Back to all studies
CompletedNCT07173439

Multi-center, Single Blinded, RCT, Pivotal Study Efficacy and Safety of DTx to Improve ADHD

This study is completed in South Korea. It focuses on ADHD.

ADHDDeviceFrom 6 Years to 12 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT07173439. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

What is this study testing?

This study is testing whether DTx may be useful for children experiencing ADHD.

What would participation involve?

Participants may receive DTx, attend study visits with the research team. The registry lists locations in South Korea.

Who is it mainly for?

This study appears to be mainly for children with ADHD. Because it involves minors, a parent or guardian may need to be involved.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.

What to expect

Your next step

The official record suggests a mix of remote and in-person participation through a clinic, with sites including Emotiv in Seoul. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis, while common reasons not to take part include safety concerns that need urgent care first and other factors that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: April 15, 2024
Recruitment status
Completed
Estimated enrollment
Not clearly listed
Sponsor
EMOTIV
Sponsor type
Unknown or unclear
Study type
Device
Intervention type
Device / app / digital / technology
Study phase
Not clearly listed
Locations
South Korea
Age range
From 6 Years to 12 Years
Official registry ID
NCT07173439
Official title
Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT07173439. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular follow-up, often through questionnaires or interviews.

Mixes in-person and remote participation.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring digital app or tool for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a device, app, or technology?

This appears to be a device / app / digital / technology study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Who might this study be for?

This study may concern people with adhd; age range: From 6 Years to 12 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to use a device, app, or digital tool for a defined period. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What should I check about data, monitoring, alerts, and daily use?

If the study uses a device, app, or digital tool, check what data is collected, who can access it, how often you need to use it, and what happens if the tool detects a concerning signal. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by EMOTIV, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me